Global Immune Checkpoint Inhibitor Market Forecast 2025-2030: Growth at 15.6% CAGR Expected

Global Immune Checkpoint Inhibitor Market Overview: 2025-2030

Base Year: 2024

Historical Years:  2020–23

Forecast Years: 2025-2030

The Global Immune Checkpoint Inhibitor Market size was valued at around USD 51.2 billion in 2023 and is projected to grow at a CAGR of 15.6% during the forecast period of 2025-30. 

Our Latest Reports Now Include In-Depth Supply Chain Ecosystem Analysis, Enabling Businesses to Navigate Tariff Challenges with Greater Agility Get Sample Report – https://www.marknteladvisors.com/query/request-sample/immune-checkpoint-inhibitors-market.html

Global Immune Checkpoint Inhibitor Market Dynamics: 2025-2030

Global Immune Checkpoint Inhibitors Market Driver:

Rising Prevalence of Cancer Cases Across the Globe Drives the Global Immune Checkpoint Inhibitors Market Growth- There are numerous reasons that thrives the demand for immune checkpoint inhibitors across the globe. One of them is the increasing commonness of cancer cases. The growing number of people diagnosing with cancer is surging notably with each successive year and fueling the demand for effective cancer treatment options. The immune checkpoint inhibitors are considered as a favorable approach in cancer treatment.

Browse Full Report with Detail Analysis – https://www.marknteladvisors.com/research-library/immune-checkpoint-inhibitors-market.html  

Global Immune Checkpoint Inhibitor Market (2025-30): Segmentation Outlook

The market report has segmented the market into the following categories:

By Drug Class

-PD- 1

-Opdivo (Nivolumab)

-Keytruda (Pembrolizumab)

-PD- L1

-Tecentriq (Atezolizumab)

-Bavencio (Avelumab)

-Imfinzi (Durvalumab)

-CTLA- 4

-Yervoy (Ipilimumab)

By Application

-Melanoma

-Hodgkin Lymphoma

-Renal Cell Cancer

-Urothelial Cancer

-Non-Small Cell Lung Cancer (NSCLC)

-Others (Head & Neck Cancers, etc.)

Out of them, the Non-Small Cell Lung Cancer segment is expected to occupy the largest share in the Global Immune Checkpoint Inhibitors in the forthcoming years. 

By End-User

-Hospitals

-Clinics

-Specialty Cancer Centers

By Region

-North America

-South America

-Europe

-Middle East & Africa

-Asia-Pacific.

Among all these regions, the North America region dominated the Immune Checkpoint Inhibitors Market in the previous year and is expected to maintain its dominance in the upcoming years as well.               

Note - If there are any particular details you need that are not currently included in the report, we will be happy to provide them as part of our customization services.

Top Companies Operating in the Global Immune Checkpoint Inhibitor Market:

-AbbVie Inc.

-Amgen Inc.

-AstraZeneca PLC

-Bluebird Bio, Inc.

-Bristol Myers Squibb

-CARsgen Therapeutics

-Eli Lilly and Company

-GlaxoSmithKline PLC

-Merck & Co., Inc.

-Novartis International AG

-Pfizer Inc.

-Regeneron Pharmaceuticals Inc.

-Sanofi S.A.

-Sun Pharmaceutical Industries Ltd.

-Others.

Industry Recent Developments:

• In February 2024, AbbVie Inc., came together with Tentarix’s Tentacles to develop new multifunctional biologics in opposed to one target in oncology and another in immunology.
• In July 2023, AstraZeneca Plc, proliferated it oncology by initiating new clinical trial new clinical trial to assess the amalgamation of its PD-L1 inhibitor with another cancer treatment. It is one of the remarkable strategic moves that aims to improve the effectiveness of its immune checkpoint inhibitors in treating solid tumors.

Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel, and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address

About Us –

We are a leading market research company, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.

Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.

Contact Us –

Email: sales@marknteladvisors.com

Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511

Address Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India